# Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

> **NCT00534313** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 191 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00534313
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2011-05
- **Target enrollment:** 191 (ACTUAL)
- **Why stopped:** Lack of efficacy with respect to skin-related lesions in the short-term phase
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534313, "Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00534313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*